Literature DB >> 24430001

The KEEPS-Cognitive and Affective Study: baseline associations between vascular risk factors and cognition.

Whitney Wharton1, Carey E Gleason2, N Maritza Dowling3, Cynthia M Carlsson2, Eliot A Brinton4, M Nanette Santoro5, Genevieve Neal-Perry6, Hugh Taylor7, Frederick Naftolin8, Rogerio A Lobo9, George Merriam10, Joann E Manson11, Marcelle I Cedars12, Virginia M Miller13, Dennis M Black14, Matthew Budoff15, Howard N Hodis16, S Mitchell Harman17, Sanjay Asthana2.   

Abstract

Midlife vascular risk factors influence later cognitive decline and Alzheimer's disease (AD). The decrease in serum estradiol levels during menopause has been associated with cognitive impairment and increased vascular risk, such as high blood pressure (BP), which independently contributes to cognitive dysfunction and AD. We describe the extent to which vascular risk factors relate to cognition in healthy, middle-aged, recently postmenopausal women enrolled in the Kronos Early Estrogen Prevention Cognitive and Affective Study (KEEPS-Cog) at baseline. KEEPS-Cog is a double-blind, randomized, placebo-controlled, parallel group, clinical trial, investigating the efficacy of low-dose, transdermal 17β-estradiol and oral conjugated equine estrogen on cognition. All results are cross-sectional and represent baseline data only. Analyses confirm that the KEEPS-Cog cohort (n = 571) was middle aged (mean 52.7 years, range 42-59 years), healthy, and free of cognitive dysfunction. Higher systolic BP was weakly related to poorer performance in auditory working memory and attention (p = 0.004; adjusted for multiple comparisons p = 0.10). This relationship was not associated with endogenous hormone levels, and systolic BP was not related to any other cognitive domain. BP levels may be more sensitive than other vascular risk factors in detecting subtle differences in cognitive task performance in healthy, recently menopausal women. Lower BP early in menopause may affect cognitive domains known to be associated with AD.

Entities:  

Keywords:  Attention; blood pressure; clinical trial; cognition; estradiol; estrogen; hormone therapy; memory; vascular risk

Mesh:

Substances:

Year:  2014        PMID: 24430001      PMCID: PMC4367860          DOI: 10.3233/JAD-130245

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  45 in total

1.  Antihypertensive drugs and incidence of dementia: the Rotterdam Study.

Authors:  B A in't Veld; A Ruitenberg; A Hofman; B H Stricker; M M Breteler
Journal:  Neurobiol Aging       Date:  2001 May-Jun       Impact factor: 4.673

2.  Angiotensin-converting enzyme inhibitors and incidence of Alzheimer's disease in Japan.

Authors:  Takashi Ohrui; Toshifumi Matsui; Mutsuo Yamaya; Hiroyuki Arai; Satoru Ebihara; Masahiro Maruyama; Hidetada Sasaki
Journal:  J Am Geriatr Soc       Date:  2004-04       Impact factor: 5.562

3.  Blood pressure-related cognitive decline: does age make a difference?

Authors:  Penelope K Elias; Merrill F Elias; Michael A Robbins; Marc M Budge
Journal:  Hypertension       Date:  2004-10-04       Impact factor: 10.190

4.  Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study.

Authors:  M Kivipelto; E L Helkala; M P Laakso; T Hänninen; M Hallikainen; K Alhainen; H Soininen; J Tuomilehto; A Nissinen
Journal:  BMJ       Date:  2001-06-16

5.  Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial.

Authors:  H N Hodis; W J Mack; R A Lobo; D Shoupe; A Sevanian; P R Mahrer; R H Selzer; C R Liu Cr; C H Liu Ch; S P Azen
Journal:  Ann Intern Med       Date:  2001-12-04       Impact factor: 25.391

6.  Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease.

Authors:  Miia Kivipelto; Eeva-Liisa Helkala; Mikko P Laakso; Tuomo Hänninen; Merja Hallikainen; Kari Alhainen; Susan Iivonen; Arto Mannermaa; Jaakko Tuomilehto; Aulikki Nissinen; Hilkka Soininen
Journal:  Ann Intern Med       Date:  2002-08-06       Impact factor: 25.391

7.  The effect of cholinesterase inhibitors on the regional blood flow in patients with Alzheimer's disease and vascular dementia.

Authors:  Wanda Lojkowska; Danuta Ryglewicz; Tomasz Jedrzejczak; Sławomira Minc; Teresa Jakubowska; Halina Jarosz; Anna Bochynska
Journal:  J Neurol Sci       Date:  2003-12-15       Impact factor: 3.181

8.  Midlife blood pressure and the risk of hippocampal atrophy: the Honolulu Asia Aging Study.

Authors:  Esther S C Korf; Lon R White; Philip Scheltens; Lenore J Launer
Journal:  Hypertension       Date:  2004-05-24       Impact factor: 10.190

9.  Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study.

Authors:  Sally A Shumaker; Claudine Legault; Lewis Kuller; Stephen R Rapp; Leon Thal; Dorothy S Lane; Howard Fillit; Marcia L Stefanick; Susan L Hendrix; Cora E Lewis; Kamal Masaki; Laura H Coker
Journal:  JAMA       Date:  2004-06-23       Impact factor: 56.272

10.  Relationships between plasma beta-amyloid peptide 1-42 and atherosclerotic risk factors in community-based older populations.

Authors:  Yoshinori Fujiwara; Makoto Takahashi; Masaharu Tanaka; Tanji Hoshi; Toshiyuki Someya; Shoji Shinkai
Journal:  Gerontology       Date:  2003 Nov-Dec       Impact factor: 5.140

View more
  14 in total

Review 1.  Postmenopausal hormone therapy and cognition.

Authors:  Anna C McCarrey; Susan M Resnick
Journal:  Horm Behav       Date:  2015-04-30       Impact factor: 3.587

Review 2.  Long-term hormone therapy for perimenopausal and postmenopausal women.

Authors:  Jane Marjoribanks; Cindy Farquhar; Helen Roberts; Anne Lethaby; Jasmine Lee
Journal:  Cochrane Database Syst Rev       Date:  2017-01-17

3.  Sex and Age Differences in the Association of Blood Pressure and Hypertension with Cognitive Function in the Elderly: The Rancho Bernardo Study.

Authors:  D Kritz-Silverstein; G A Laughlin; L K McEvoy; E Barrett-Connor
Journal:  J Prev Alzheimers Dis       Date:  2017

4.  Plasma orexin A levels in recently menopausal women during and 3 years following use of hormone therapy.

Authors:  Dahima Cintron; John P Beckman; Kent R Bailey; Brian D Lahr; Muthuvel Jayachandran; Virginia M Miller
Journal:  Maturitas       Date:  2017-02-17       Impact factor: 4.342

5.  Differential effects of hormone therapy on serotonin, vascular function and mood in the KEEPS.

Authors:  L Raz; L V Hunter; N M Dowling; W Wharton; C E Gleason; M Jayachandran; L Anderson; S Asthana; V M Miller
Journal:  Climacteric       Date:  2015-12-10       Impact factor: 3.005

6.  Identifying postmenopausal women at risk for cognitive decline within a healthy cohort using a panel of clinical metabolic indicators: potential for detecting an at-Alzheimer's risk metabolic phenotype.

Authors:  Jamaica R Rettberg; Ha Dang; Howard N Hodis; Victor W Henderson; Jan A St John; Wendy J Mack; Roberta Diaz Brinton
Journal:  Neurobiol Aging       Date:  2016-01-29       Impact factor: 4.673

7.  Pharmacogenomics of estrogens on changes in carotid artery intima-medial thickness and coronary arterial calcification: Kronos Early Estrogen Prevention Study.

Authors:  Virginia M Miller; Gregory D Jenkins; Joanna M Biernacka; John A Heit; Gordon S Huggins; Howard N Hodis; Matthew J Budoff; Rogerio A Lobo; Hugh S Taylor; JoAnn E Manson; Dennis M Black; Frederick Naftolin; S Mitchell Harman; Mariza de Andrade
Journal:  Physiol Genomics       Date:  2015-10-27       Impact factor: 3.107

Review 8.  Precision hormone therapy: identification of positive responders.

Authors:  Y J Kim; R D Brinton
Journal:  Climacteric       Date:  2021-02-22       Impact factor: 3.005

Review 9.  Interactions between estradiol, diabetes, and brain aging and the risk for cognitive impairment.

Authors:  C E Hugenschmidt; T Duran; M A Espeland
Journal:  Climacteric       Date:  2021-02-15       Impact factor: 3.024

10.  Lessons from KEEPS: the Kronos Early Estrogen Prevention Study.

Authors:  V M Miller; H S Taylor; F Naftolin; J E Manson; C E Gleason; E A Brinton; J M Kling; M I Cedars; N M Dowling; K Kantarci; S M Harman
Journal:  Climacteric       Date:  2020-09-03       Impact factor: 3.005

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.